BHC Bausch Health Companies Inc.

24.49
+0.26  (+1%)
Previous Close 24.23
Open 24.24
Price To Book 3.27
Market Cap 8563368095
Shares 349,667,950
Volume 4,095,121
Short Ratio 2.62
Av. Daily Volume 3,833,922

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced May 7, 2018.
Plenvu (NER1006)
Bowel cleansing
Approval announced November 2, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
FDA approval announced February 25, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approval announced December 22, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
FDA Approval announced August 24, 2018.
IDP-121
Acne
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-122
Psoriasis
NDA filing due 2020.
IDP-120
Acne
FDA approval announced April 25, 2019.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
NDA filed.
IDP-123
Psoriasis
Approved February 15, 2017.
Brodalumab
Psoriasis
Approval announced March 2, 2018.
ULTRA - 7 days
Contact lens
FDA decision due May 2019 or July 2019.
EM-100
Allergic conjunctivitis
Phase 2 top-line data due 1H 2019.
IDP-126
Acne